

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9 (cancelled).

Claim 10-16 (withdrawn).

Claims 17-32 (cancelled).

Claim 33-43 (withdrawn).

Claim 44 (previously presented): A pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of a dermal cytochrome A450 1A (CYP1A), and a carrier, wherein said dermal CYP1A inhibitor is terpineol; and wherein said pharmaceutical composition is applied to skin of a mammal together with a dermatological drug.

Claim 45 (cancelled).

Claim 46-47 (withdrawn).

Claim 48 (previously presented): The pharmaceutical composition according to claim 44, wherein said dermatological drug is retinoic acid or retinoid.

Claim 49 (currently amended): A topical pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of a dermal cytochrome P450 1A (CYP1A) inhibitor, a carrier, and a dermatological drug;

wherein said dermal CYP1A inhibitor is ~~at least one selected from the group consisting of~~
~~(-) epicatechin, (+) epicatechin, (+) limonene, 3-phenylpropyl acetate, apigenin, baicalein,~~
~~baicalin, β -myrcene, catechin, β -naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol,~~
~~formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin,~~

~~isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin 7 glycoside, narigin,
nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, terpineol,
trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin,
neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.~~

Claim 50 (previously presented): The topical pharmaceutical composition according to claim 49, wherein said CYP1A inhibitor is terpineol and said dermatological drug is retinoic acid or retinoid.

Claim 51 (previously added): The topical pharmaceutical composition according to claim 49, wherein said CYP1A inhibitor is in the amount of about 10% by weight of said pharmaceutical composition.